Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a ...
In a response to the US SEC decision Sanofi neither admitted nor denied any wrongdoing, but confirmed it will pay $25.2 million and agreed to a two-year period of self-reporting on effectiveness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback